Indication
Acute Myeloid Leukemia With NPM1 Mutation
1 clinical trial
2 products
Clinical trial
Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients With Relapsed/Refractory FLT3- Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase I (Ph I) Study of SNDX-5613 + GilteritinibStatus: Recruiting, Estimated PCD: 2025-12-31
Product
GilteritinibProduct
Revumenib